Posted by Michael Wonder on 13 Oct 2016
Valeant hiked lead poisoning drug price by 2,700 per cent: report
11 October 2016 - Valeant Pharmaceuticals hiked the price of a widely used treatment for life-threatening cases of lead poisoning by more than 2,700 per cent in a single year, according to a U.S. medical news source.
Valeant acquired the drug known as Calcium EDTA in 2012 as part of a US$2.6-billion deal to buy Arizona-based Medicis.
The Quebec-based drug maker is said to have boosted the list price from $950 to $7,116 following the acquisition, and then raised the price to $26,927 through a series of increases over course of 2014, according to data from Truven Health Analytics.
